Hello, everyone, and how are you today? We are doing just fine, thank you, especially since a spot of snow has generated a lovely wintry scene outside our window. Moreover, the middle of the week is upon us and since we have made it this far, we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get started. Our flavor today is strawberry creme — sweets for the sweet, you know? And now … onward. Here are a few items of interest to help you get started. We hope you have a lovely day, and do keep in touch. …
A U.S. judge ordered government agencies to restore public access to health-related webpages and datasets that they removed to comply with an executive order by President Trump, the Associated Press writes. U.S. District Judge John Bates in Washington agreed to issue a temporary restraining order requested by the Doctors for America advocacy group. The judge instructed the government to restore access to several webpages and datasets that the group identified as missing from websites and to identify others that also were taken down “without adequate notice or reasoned explanation.” Doctors for America, which was represented by the Public Citizen Litigation group, sued the Office of Personnel Management, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, and the U.S. Department of Health and Human Services.
With few exceptions, the pharmaceutical industry is favoring appeasement and behind-the-scenes engagement with the Trump administration on health care policy, rather than arguing in public in a way that risks triggering the president, STAT explains. This circumspect approach comes amid a policy change at the U.S. National Institutes of Health that would slash funding for research overhead to universities and academic medical research centers. The NIH decision could have a severe impact on early biomedical research that leads to breakthrough treatments, according to warnings from scientists, university leaders, and even some Republicans. STAT reached out to a broad swath of biotech and pharma executives, Wall Street analysts, and other observers, seeking to understand why the industry has chosen not to publicly defend universities and other academic research institutions facing steep cuts in NIH funding. No one was willing to speak on the record.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in